TXMDHealthcare · Drug Manufacturers - Specialty & Generic

TXMD Stock Forecast: TherapeuticsMD, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026

$2.16

0.00% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 12 Sept 2026 — inside the top quartile.

Market cap

$24.3M

Ticker Nerd rank

80 / 100

Median analyst target

—

Analysts covering

Revenue$724K+84.2% y/y

Operating income−$723K

Net income$95K

Free cash flow$944K

Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown

Total return, dividends reinvested

−2.3%

+4.3%

YTD

+32.5%

+94.6%

From 52W high

−22.0%

From 52W low

+107.7%

$1.04

$2.77

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

TXMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores TherapeuticsMD, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026

80 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Momentum

Issuance

Accruals

Volatility

Value

Quality

Growth

Revisions

Size (87): Smaller than most of the companies we track.

Revisions (25): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TXMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TXMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts

8 Buy1 Hold0 Sell

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 6 moved it down.

Date	Firm	Action	Rating	Target
17 Aug 2023	Cantor Fitzgerald	Reiterates	Neutral	$5.00
17 Aug 2023	Cantor Fitzgerald	Reiterates	Neutral	—
11 Jan 2023	Cantor Fitzgerald	Reinstates	Neutral	$5.00
13 July 2022	Cantor Fitzgerald	Reiterates	Neutral	—
7 June 2022	HC Wainwright & Co.	Downgrade	Neutral	—
6 May 2022	Cantor Fitzgerald	Downgrade	Neutral	$5.00 → $1.00
11 Mar 2022	HC Wainwright & Co.	Maintains	Buy	$3.00 → $2.50
12 Nov 2021	HC Wainwright & Co.	Maintains	Buy	$4.00 → $3.00
7 Aug 2020	Jefferies	Downgrade	Underperform	$1.25 → $1.20
19 May 2020	JP Morgan	Downgrade	Neutral	—
7 May 2020	H.C. Wainwright	Reiterates	Buy	—
7 May 2020	HC Wainwright & Co.	Reiterates	Buy	$6.00 → $5.00
16 Apr 2020	Stifel	Maintains	Buy	$14 → $15
21 Feb 2020	H.C. Wainwright	Maintains	Buy	—
21 Feb 2020	HC Wainwright & Co.	Maintains	Buy	$7.00 → $6.00
14 Aug 2018	Cantor Fitzgerald	Maintains	Overweight	$26 → $27
15 June 2018	JP Morgan	Initiates	Overweight	—
8 Sept 2017	Morgan Stanley	Initiates	Equal-Weight	—
21 July 2017	Deutsche Bank	Initiates	Buy	—
11 July 2017	Oppenheimer	Upgrade	Outperform	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TXMD appears on the weeks it earns a place.

Performance

TXMD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, TherapeuticsMD, Inc. returned +94.6% against +17.0% for the S&P 500, dividends included.

TXMD vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TXMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

TherapeuticsMD, Inc. (TXMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 207.0×
Price / sales: 7.6×
Price / book: 0.9×
EV / EBITDA: −15.6×

Growth & margins

Revenue growth (YoY): −8.7%
Earnings growth (YoY): −71.9%
Gross margin: —
Operating margin: −32.2%
Net margin: −6.6%

Returns & dividend

Return on equity: −1.1%
Return on assets: −2.9%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

TherapeuticsMD, Inc. (TXMD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

TherapeuticsMD, Inc. has a market value of $24.3M and an enterprise value of $21.4M.
Revenue in the twelve months to 31 Mar 2026: $3.4M. The latest quarter shrank 8.7% year on year.
Net income over the same four quarters: $179K, a 5.3% net margin.
Free cash flow in the twelve months to 31 Mar 2026: $2.7M.
Shares outstanding: 11.6M.
Trailing P/E: 207.0×; forward P/E: 6.2× — the forward figure prices analyst consensus estimates, not reported earnings.
TherapeuticsMD, Inc. employs 1 people — $3.4M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

TXMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic

Company	Market cap	TKN rank
TXMDTherapeuticsMD, Inc.	$24.3M	80
OPTHOptimi Health Corp.	$25.9M	10
BFRIBiofrontera, Inc.	$23.0M	67
UPCUniverse Pharmaceuticals, Inc.	$21.9M	34
AYTUAytu Biopharma, Inc.	$21.4M	65
RMTIRockwell Medical, Inc.	$31.4M	47
CPHIChina Pharma Holdings, Inc.	$32.7M	49

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own TherapeuticsMD, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TXMD news & analysis

TherapeuticsMD Announces Second Quarter 2026 Financial Results

Business Wire · 11 Aug 2026negative

TherapeuticsMD reported financial results for the three months ended June 30, 2026, with net income from continuing operations of $164 thousand, compared to $545 thousand in the second quarter of 2025. The report also covered license revenues from continuing operations.

Why it matters — TXMD watchers would care because the company's reported quarterly net income from continuing operations declined compared to the prior-year quarter, indicating a shift in its royalty-focused earnings.

FAQ

Frequently asked questions about TXMD stock

Is TXMD stock a buy right now?

Of the 9 analysts covering TherapeuticsMD, Inc., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TherapeuticsMD, Inc. 80 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TXMD?

As at 12 Sept 2026, TherapeuticsMD, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (87 of 100).

What is the TXMD stock forecast for 2030?

No analyst covering TherapeuticsMD, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TXMD are extrapolating price history, which says nothing about the business.

How has TXMD stock performed over the past year?

TherapeuticsMD, Inc. returned +94.6% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does TherapeuticsMD, Inc. do?

TherapeuticsMD, Inc. is a pharmaceutical royalty company focused on women’s health.

What is the latest news on TXMD?

The most recent item we track (Business Wire, 11 Aug 2026): "TherapeuticsMD Announces Second Quarter 2026 Financial Results". TherapeuticsMD reported financial results for the three months ended June 30, 2026, with net income from continuing operations of $164 thousand, compared to $545 thousand in the second quarter of 2025. The report also covered license revenues from continuing operations.

Company

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is a pharmaceutical royalty company focused on women’s health. TherapeuticsMD licenses and commercializes prescription products used in menopause management, contraception, and reproductive health, including BIJUVA, IMVEXXY, and ANNOVERA, through its licensing partners. The company also offers prescription prenatal vitamin products under the BocaGreenMD and vitaMedMD brands. Its business is centered on supporting women across key life stages by providing hormone therapy, family planning, and prenatal care products. TherapeuticsMD operates with a licensing-based model that emphasizes product access, brand development, and ongoing royalties within the women’s healthcare market. Headquartered in Boca Raton, Florida, TherapeuticsMD serves as a specialized participant in the pharmaceutical industry with a narrow focus on women’s health products and related therapeutic categories.

1 employees · United States · https://www.therapeuticsmd.com